Mendis S, Somasiri K G, Chularatna W
Department of Physiology, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
Ceylon Med J. 1993 Dec;38(4):174-7.
To investigate whether drug treatment improves the electroneurological measures of affected peripheral nerve function in leprosy patients.
Clinical status of patients determined on the first visit by an investigator administered, pre-designed questionnaire, followed by measurement of motor conduction velocity (MCV) and distal latency (DL) of ulnar, median, common peroneal and posterior tibial nerves bilaterally in patients referred consecutively from the dermatology unit and leprosy clinic, Teaching Hospital, Galle. MCV and DL measurements were repeated after 6 to 12 months of treatment.
Department of Physiology, Faculty of Medicine, University of Ruhuna, Galle.
24 diagnosed leprosy patients; tuberculoid, lepromatous and borderline in clinical type.
Based on clinical typing. Tuberculoid (paucibacillary) type rifampicin 600 mg monthly and dapsone 100 mg daily for six months. Lepromatous and borderline (multibacillary) type rifampicin 600 mg and clofazimine 300 mg monthly and dapsone 100 mg and clofazimine 50 mg daily for 24 months.
DL in all 4 nerves and MCV in 3 nerves tested were significantly different (p > 0.001) to those for the normal population and remained so after 6 to 12 months of treatment. The DL in the ulnar nerve showed significant improvement (p < 0.05) after treatment. When analysed in each patient individually, before and after treatment, the MCV showed an improvement in 48 to 72% of patients and the DL in 41 to 59%, but differences were not significant.
Electroneurological recovery (return to normal state) of the affected peripheral nerves of leprosy patients does not occur after 6 to 12 months of drug treatment. The significant (p < 0.05) improvement (becoming better) of ulnar nerve DL indicates that, if at all, electroneurologically detectable improvement of nerve function occurs in the early stages of nerve damage, and that it may take longer than one year after starting treatment.
研究药物治疗是否能改善麻风患者受累周围神经功能的神经电生理指标。
由一名研究人员通过预先设计的问卷确定患者首次就诊时的临床状况,随后对从加勒教学医院皮肤科和麻风病诊所连续转诊的患者双侧尺神经、正中神经、腓总神经和胫后神经的运动传导速度(MCV)和远端潜伏期(DL)进行测量。治疗6至12个月后重复进行MCV和DL测量。
鲁胡纳大学医学院生理学系,加勒。
24例确诊的麻风患者;临床类型为结核样型、瘤型和界线类。
根据临床分型。结核样型(少菌型)每月服用利福平600毫克,每日服用氨苯砜100毫克,持续六个月。瘤型和界线类(多菌型)每月服用利福平600毫克和氯法齐明300毫克,每日服用氨苯砜100毫克和氯法齐明50毫克,持续24个月。
所检测的4条神经的DL以及3条神经的MCV与正常人群相比均有显著差异(p>0.001),且在治疗6至12个月后仍保持如此。尺神经的DL在治疗后有显著改善(p<0.05)。在对每位患者治疗前后进行单独分析时,MCV在48%至72%的患者中有所改善,DL在41%至59%的患者中有所改善,但差异不显著。
麻风患者受累周围神经在药物治疗6至12个月后未出现神经电生理恢复(恢复至正常状态)。尺神经DL的显著(p<0.05)改善表明,若神经功能在神经电生理方面有可检测到的改善,那也是在神经损伤的早期阶段,且可能在开始治疗一年后才会出现。